Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorIhara, Keiko
dc.contributor.authorCasillo, Francesco
dc.contributor.authorDahshan, Ahmed
dc.contributor.authorGenç, Hamit
dc.contributor.authorJusupova, Asel
dc.contributor.authorKarbozova , Kunduz
dc.contributor.authorPozo-Rosich, Patricia
dc.date.accessioned2024-10-28T11:55:42Z
dc.date.available2024-10-28T11:55:42Z
dc.date.issued2024-09
dc.identifier.citationIhara K, Casillo F, Dahshan A, Genç H, Jusupova A, Karbozova K, et al. Are we closer to achieving precision medicine for migraine treatment? A narrative review. Cephalalgia. 2024;44(9):1-14.
dc.identifier.issn1468-2982
dc.identifier.urihttps://hdl.handle.net/11351/12138
dc.descriptionMigraine; Prediction; Treatment
dc.description.abstractBackground The term ‘precision medicine’ encompasses strategies to optimize diagnosis and outcome prediction and to tailor treatment for individual patients, in consideration of their unique characteristics. The greater availability of multifaceted datasets and strategies to model such data have made precision medicine increasingly possible in recent years. Precision medicine is especially needed in the migraine field since the response to migraine treatments is not universal amongst all individuals with migraine. Objective To provide a narrative review describing contributions to achieving precision medicine for migraine treatment. Methods A search of PubMed for English language articles of human participants published from 2005 to January 2024 was conducted to identify articles that reported research contributing to precision medicine for migraine treatment. The published literature was categorized and summarized according to the type of data that were included: clinical phenotypes, genomics, proteomics, physiologic measures, and brain imaging. Results Published studies have investigated characteristics associated with acute and preventive treatment responses, such as nonsteroidal anti-inflammatory drugs, triptans, onabotulinumtoxinA, and anti-calcitonin gene-related peptide monoclonal antibodies, in patients with episodic or chronic migraine. There is evidence that clinical, genetic, epigenetic, proteomic, physiologic, and brain imaging features might associate with migraine treatment outcomes, although inconsistencies for such findings clearly exist. Conclusions The published literature suggests that there are clinical and biological features which associate with, and might be useful for predicting, migraine treatment responses. To achieve precision medicine for migraine treatment, further research is needed that validates and expands on existing findings and tests the accuracy and value of migraine treatment prediction models in clinical settings.
dc.language.isoeng
dc.publisherSAGE Publications
dc.relation.ispartofseriesCephalalgia;44(9)
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectMigranya - Tractament
dc.subjectMigranya - Diagnòstic
dc.subjectMedicina personalitzada
dc.subject.meshMigraine Disorders
dc.subject.mesh/diagnosis
dc.subject.meshPrecision Medicine
dc.titleAre we closer to achieving precision medicine for migraine treatment? A narrative review
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1177/03331024241281518
dc.subject.decstrastornos migrañosos
dc.subject.decs/diagnóstico
dc.subject.decsmedicina de precisión
dc.relation.publishversionhttps://doi.org/10.1177/03331024241281518
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Ihara K] Department of Neurology, Keio University School of Medicine, Tokyo, Japan. Neurology Department, Japanese Red Cross Ashikaga Hospital, Ashikaga, Japan. [Casillo F] Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino ICOT, Latina, Italy. [Dahshan A] Department of Neurology, Cairo University, Cairo, Egypt. [Genç H] Department of Neurology, Gaziantep City Hospital, Gaziantep, Türkiye. [Jusupova A, Karbozova K] Department of Neurology and Clinical Genetics, Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan. [Pozo-Rosich P] Unitat de Cefalea, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca de Cefalea i Dolor Neurològic, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid39256924
dc.identifier.wos001328346500003
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record